Matricelf produces in-house induced pluripotent stem cells

Matricelf (TASE-MTLF) reported today that it has produced in-house induced pluripotent stem cells (iPSCs) from human peripheral blood cells. The company reprogrammed the cells into iPSCs, which presented specific characteristics of differentiation as pluripotent stem cells.

Induced pluripotent stem cells have the ability to differentiate into different cell types, including neural cells, and by combining the cells with the unique hydrogel, developed by the company, they will assemble the autologous 3D neural implant for paralyzed patients, after spinal cord injury.

Matricelf develops 3D autologous implants for the regeneration of damaged tissue, using a cellular and extracellular component, both derived from the patients themselves. The company was founded in 2019 by Alon Sinai and Prof Tal Dvir, who serves as the company’s chief researcher. Based in Ness Ziona, Matricelf has 11 employees.

The implant manufacturing process combines proprietary technology to produce a thermo-responsive hydrogel using the patient’s omentum (intra-abdominal adipose tissue) and iPSCs generated by reprogramming mature cells from the patient’s peripheral blood.

The company believes that self-manufacturing of iPSCs is an important milestone that the R&D team has achieved as part of the preclinical company’s R & D program. The ability to independently produce iPSCs, in parallel with the completion of hydrogel development, is a crucial step towards end-to-end independent production capacity of neural tissue implants.

Matricelf’s CEO Dr. Asaf Toker said: “Our ability to independently produce human iPSCs is a huge achievement for the R&D team in both the scientific and business aspects. The ability to produce iPSCs without having to rely on external subcontractors positions the company as a key player in the cellular therapy and regenerative medicine industry and will reduce future production costs.We believe that independent production capacity of iPSCs is a remarkable economic opportunity in a market worth billions of dollars a year dealing with spinal cord injury and in the future for a variety of other medical conditions.

Matricelf VP R&D, Dr. Tamar Harel Adar added: “The process of reprogramming mature cells to iPSC, which allows for differentiation to any cell type, is a revolutionary and promising technology in the world of cellular therapy and regenerative medicine. Independent production capabilities of iPSCs are a result of intensive work from the R & D team, based on acquiring and developing useful know-how and scientific tools.The ability to manufacture iPSCs from the patient’s own mature cells is significant as it enables the company to produce new tissue to replace various human damaged tissue in a variety of medical conditions. “

Published by Globes, Israel business news – – on May 1, 2022.

© Copyright by Globes Publisher Itonut (1983) Ltd., 2022.

Leave a Comment